couter

4575.TCanBas Co., Ltd.

Health CareBiotechnology
Nov 13, 2026 — Q1 FY2027 Earnings Release
Chart by TradingView

The schedule

  • Fri13Nov

    Market assessment of CanBas's operational cash burn and runway for the quarter ending September 30, 2026.

  • Wed20Jan

    Expected early 2027 clinical progression update and regulatory guidance for the lead oncology asset, CBP501.

  • Fri12Feb

    Fiscal Q2 earnings update focusing on capitalized R&D sustaining the Phase 2/3 pipeline.

  • Sat1May

    Market pricing of dilution risk as cash reserves deplete ahead of further late-stage clinical milestones.

  • Fri14May

    Third-quarter financial results detailing post-raise liquidity and trial acceleration.